Tolerability and clinical activity of novel first-in-class oral agent, inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Tolerability and clinical activity of novel first-in-class oral agent, inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma